- JanOne Inc JAN has acquired an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO).
- The agreement with LSU Health Shreveport and other intellectual property relating to TSPO's role in treating meth use disorder (MUD) provides JanOne with an opportunity to identify new drugs to enhance TSPO activity.
- JanOne anticipates starting a drug discovery program in 2022 to identify a preclinical IND-candidate in 2023.
- JanOne held Cash and cash equivalents of $2.82 million as of October 2, 2021.
- Price Action: JAN shares are trading higher by 5.51% at $4.79 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
